Factor 8 Ehl denied as non-formulary by Humana?

Humana's specific coverage criteria for factor 8 ehl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Extended Half-Life Factor VIII as Non-Formulary

Humana's drug formulary — its approved list of covered medications — typically includes at least one standard-acting Factor VIII concentrate at a preferred tier. Extended half-life (EHL) Factor VIII products may be placed on a non-preferred tier, a specialty tier requiring separate approval, or excluded from the formulary entirely. When a prescription is submitted for an EHL product not on the preferred tier, Humana will issue a non-formulary denial before reviewing clinical merit.

## Why This Denial Is Appealable

Formulary placement is a coverage decision, not a final determination of what is medically appropriate for your specific situation. Most plans allow a formulary exception when a preferred alternative is contraindicated, clinically inappropriate, or has already been tried and failed. EHL Factor VIII products have distinct pharmacokinetic profiles compared with standard products; your hematologist can document why the non-preferred EHL product is specifically necessary for you.

## Federal Appeal Rights

• ERISA §503 (employer plans): Full-and-fair internal review is required before external review.
• ACA §2719 (non-grandfathered individual/small-group plans): External review by an IRO is available after internal denial. The request window is typically around four months from the denial — verify your exact deadline on the denial letter.
• Expedited track: Available when delay would seriously jeopardize health or the ability to regain maximum function.

## Appeal Process and Timeline

1. Request a formulary exception in writing simultaneously with or instead of a standard appeal — many plans have a dedicated exception pathway that is faster. 2. If the exception is denied, escalate to a Level 1 internal appeal. 3. After exhausting internal options, file for external IRO review within your plan's deadline.

## Documentation to Gather

• Formulary alternatives tried: Names, dates, doses, and documented reasons for discontinuation or inadequacy of any preferred-tier Factor VIII products.
• Clinical rationale for the specific EHL product: Prescriber letter explaining why the non-preferred EHL formulation is medically necessary — for example, unique pharmacokinetic characteristics that match the patient's lifestyle or adherence profile.
• Diagnosis and severity documentation: Lab-confirmed Hemophilia A, Factor VIII activity level, annual bleed rate, target-joint assessment.
• FDA-approved labeling: Include the product's label to demonstrate it is an FDA-approved treatment for Hemophilia A.
• Guideline support: Reference to WFH and MASAC guidance that supports EHL product use in your patient population.

## Criteria-Mapping Structure

Pull Humana's current formulary and the formulary exception criteria from the Evidence of Coverage or Benefits Summary. Then map:

| Exception Criterion | Supporting Evidence | |---|---| | Preferred alternative tried and failed or contraindicated | Pharmacy records, provider notes | | Specific medical need for non-preferred EHL product | Prescriber letter with clinical reasoning | | FDA approval status of requested product | Prescribing label excerpt | | Specialty prescriber attestation | Hematologist signature and credentials |

A well-mapped exception request often resolves a non-formulary denial at the first level without requiring a full external review.